Group 1 - The People's Bank of China has decided to lower the foreign exchange risk reserve ratio for forward foreign exchange sales from 20% to 0% starting March 2, 2026, to support enterprises in managing exchange rate risks and promote the development of the foreign exchange market [1] - The A-share merger and acquisition market has seen over 500 transactions since the beginning of the year, with a total value of approximately 130 billion yuan, marking a year-on-year increase in activity, particularly in the hard technology sector [1] Group 2 - In 2026, China plans to implement two manned spaceflight missions and one cargo supply mission, while also advancing the construction of lunar landing support facilities [2] - IDC forecasts a 12.9% decline in the global smartphone market in 2026 due to an unprecedented shortage of storage chips, which poses a significant threat to many smartphone manufacturers' business models [2] Group 3 - The cement industry is experiencing a positive start to 2026 with major projects commencing, although overall cement prices are expected to decline throughout the year [3] - The AI industry is entering a phase focused on commercial viability, with significant investment opportunities emerging in domestic AI chip development [3] Group 4 - Several domestic chip companies have announced price increases of at least 10% due to rising costs of upstream raw materials and key precious metals [5] - The controlled nuclear fusion sector is attracting significant investment from state-owned and industrial capital, indicating a growing interest in this technology as a potential solution to energy supply issues [5] Group 5 - Netflix has opted not to increase its bid for Warner Bros, allowing Paramount to win the acquisition, as Netflix deemed the deal financially unattractive [6] - Li Ka-shing's companies have agreed to sell their 100% stake in UK Power Networks for over 110 billion Hong Kong dollars, which will provide substantial accounting gains and cash for future investments [6] Group 6 - Stellantis reported a net loss of 22.3 billion euros for 2025, primarily due to restructuring costs, despite signs of recovery in the latter half of the year [7] - A dental robotics company, Shanghai Yangshan Medical Technology, has completed nearly 100 million yuan in Pre-A financing, led by a strategic investment from Aidi Tech [7] Group 7 - Jianghe Creation announced that an independent director is unable to perform duties due to involvement in a legal case, although it does not affect the company's operations [8] - Luyuan Energy reported a 20.49% decline in net profit for 2025, attributed to exchange rate fluctuations and increased management costs [12] Group 8 - The stock price of Beiliang Technology fell significantly due to a 28.94% decline in revenue and a net loss of approximately 89.3 million yuan for 2025 [14] - Teruide has submitted an application for H-share listing on the Hong Kong Stock Exchange [16]

Core Viewpoint - The company announced the resignation of its president and board member, Ren Hui, due to work-related changes, effective immediately upon delivery of the resignation report to the board [1] Group 1 - Ren Hui submitted a written resignation report on February 26, indicating his intention to resign from the positions of director, president, legal representative, and member of the strategic and ESG committee [1] - Following his resignation, Ren Hui will no longer hold any position within the company [1]

Group 1 - The company announced that its board received a resignation report from Mr. Ren Hui, the director and president, on February 26, 2026 [1] - Mr. Ren Hui is resigning from his positions as a member of the eighth board of directors, the Strategic and ESG Committee, and as president and legal representative due to work changes [1] - The resignation of Mr. Ren Hui will not affect the company's normal production and operations [1]

Core Viewpoint - Ren Hui has resigned from his positions as a director, member of the Strategy and ESG Committee, president, and legal representative of Boya Bio (300294) due to work-related changes, and this resignation will not affect the company's normal production operations [1] Group 1 - Ren Hui's resignation will not impact the company's normal production operations [1] - As of the announcement date, Ren Hui does not hold any shares in the company [1] - There are no unfulfilled commitments that Ren Hui is obligated to fulfill [1]

博雅生物（300294）(300294.SZ)发布公告，公司董事会于2026年2月26日收到公司董事、总裁任辉先生 递交的书面《辞任报告》，任辉先生因工作变动原因申请辞去公司第八届董事会董事、战略与ESG委员 会委员及总裁、法定代表人的职务，辞任后将不再担任公司任何职务。任辉先生的辞任不会影响公司的 正常生产运营。 ...

任辉先生作为公司董事、总裁及相关岗位，原定任期至2027年03月20日止。 在其任职期间，任辉先生始终恪尽职守、勤勉尽责，积极推动公司的规范运作与 健康发展，发挥了重要作用。公司董事会对任辉先生在任职期间为公司发展做出 的努力和贡献表示衷心感谢！ 特此公告。 华润博雅生物制药集团股份有限公司董事会 2026 年 2 月 27 日 关于公司董事暨总裁辞任的公告 本公司及董事会全体成员保证公告内容真实，准确和完整，没有虚假记载， 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）董事会于2026年2月 26日收到公司董事、总裁任辉先生递交的书面《辞任报告》，任辉先生因工作变 动原因申请辞去公司第八届董事会董事、战略与ESG委员会委员及总裁、法定代 表人的职务，辞任后将不再担任公司任何职务。任辉先生的辞任不会影响公司的 正常生产运营。截至本公告披露日，任辉先生未持有公司股份，不存在应履行而 未履行的承诺事项。 任辉先生的辞任未导致公司董事会人数低于法定最低人数，不会影响公司董 事会及生产经营的正常运作，根据《中华人民共和国公司法》《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规 ...

Pharmaceutical Sector - Changchun Gaoxin's new drug for treating developmental disorders in boys has significantly impacted its stock price, but the company has stated that the project is still in the early stages [1] - Boya Bio plans to focus its future research on gene therapy and antibody drugs [1] Robotics Sector - Liard's robotics business falls under the AI and spatial computing segment, contributing approximately 5% to total revenue [1] - Liard has established partnerships with several well-known domestic and international robotics manufacturers [1] - Sanrui Technology's intelligent sensor chips are not applied in humanoid robots [1] Battery Sector - Wanshun New Materials has begun small-scale supply of aluminum foil for high-capacity batteries [1] Chemical Sector - Yahua Group reports that the current export ban in Zimbabwe will not affect its normal production and operations [1] - Dongyue Silicon Material is actively engaging the market with its liquid glue products [1]

Core Viewpoint - Boya Bio's stock performance shows a slight increase, with significant financing activities indicating high investor interest and potential volatility in the market [1][2]. Financing Summary - On February 25, Boya Bio recorded a financing buy amount of 12.34 million yuan, with a net financing purchase of 2.61 million yuan, indicating strong demand for its shares [1]. - The total financing and securities balance reached 686 million yuan, representing 6.07% of the circulating market value, which is above the 80th percentile of the past year [1]. - The company also experienced a high level of short selling, with a short selling balance of 2.73 million yuan, exceeding the 90th percentile of the past year [1]. Business Performance - For the period from January to September 2025, Boya Bio achieved a revenue of 1.47 billion yuan, reflecting a year-on-year growth of 18.38%, while the net profit attributable to shareholders decreased by 16.90% to 343 million yuan [2]. - The company's main business segments include blood products (84.58% of revenue), biochemical drugs (8.63%), distribution business (6.12%), and other businesses (0.65%) [1]. Shareholder Information - As of February 13, the number of shareholders for Boya Bio was 31,600, a decrease of 0.27% from the previous period, while the average circulating shares per person increased by 0.27% to 15,959 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 8.88 million shares, a decrease of 1.82 million shares from the previous period [3].

Group 1 - The core inquiry from investors is whether China Resources Group possesses blood station resources and if it will inject these into Boya Bio [2] - Boya Bio (300294.SZ) confirmed on the investor interaction platform that it is part of the China Resources Health sector's blood products platform [2] - As of now, Boya Bio holds a total of 2 blood product production licenses and operates 21 single plasma collection stations, including 4 under the Green Cross brand [2]

Group 1 - The core issue raised by investors concerns the adjustment of the value-added tax (VAT) rate from 3% to 13% and its potential impact on the company's tax costs and profits [1] - The company clarified that rare disease drugs within blood products, such as PCC and factors VIII and IX, will continue to be subject to the 3% simplified tax rate, while other blood product businesses will no longer qualify for this rate [1] - The company emphasized its commitment to improving supply chain management and operational practices in response to tax policy changes, aiming to create value for the company and its shareholders [1]